SCYX vs. INBX, ACRV, PRQR, ACRS, IKT, ACTU, SCPH, ALEC, GLSI, and LYEL
Should you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include Inhibrx (INBX), Acrivon Therapeutics (ACRV), ProQR Therapeutics (PRQR), Aclaris Therapeutics (ACRS), Inhibikase Therapeutics (IKT), Actuate Therapeutics (ACTU), scPharmaceuticals (SCPH), Alector (ALEC), Greenwich LifeSciences (GLSI), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry.
SCYNEXIS vs.
SCYNEXIS (NASDAQ:SCYX) and Inhibrx (NASDAQ:INBX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and profitability.
SCYNEXIS received 474 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 70.04% of users gave SCYNEXIS an outperform vote while only 58.49% of users gave Inhibrx an outperform vote.
SCYNEXIS has higher revenue and earnings than Inhibrx.
Inhibrx has a net margin of 0.00% compared to SCYNEXIS's net margin of -425.41%. SCYNEXIS's return on equity of -66.21% beat Inhibrx's return on equity.
In the previous week, Inhibrx had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 2 mentions for Inhibrx and 1 mentions for SCYNEXIS. Inhibrx's average media sentiment score of 0.33 beat SCYNEXIS's score of 0.00 indicating that Inhibrx is being referred to more favorably in the news media.
54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx shares are owned by institutional investors. 2.9% of SCYNEXIS shares are owned by insiders. Comparatively, 22.2% of Inhibrx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
SCYNEXIS beats Inhibrx on 8 of the 14 factors compared between the two stocks.
Get SCYNEXIS News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
SCYNEXIS Competitors List
Related Companies and Tools
This page (NASDAQ:SCYX) was last updated on 2/18/2025 by MarketBeat.com Staff